In a significant policy proposition published on the last Friday, the U.S. Food and Drug Administration (FDA) revealed plans to explicitly categorise in vitro diagnostic products (IVDs), including those where the manufacturer is a laboratory, as medical devices. This comes in compliance with the Federal Food, Drug, and Cosmetic Act (FDCA), thus entrusting the FDA with their regulation. Hogan Lovells provides a detailed insight into this regulatory move.
In specific, the FDA is set to progressively phase out its enforcement discretion approach for laboratory developed tests (LDTs) by the year 2028. This prospective shift in the regulatory approach could have striking implications. Legal professionals in pharmaceutical and healthcare companies, as well as associated law firms, need to closely watch the developments, not only to comprehend their impact but also to adapt strategies and operations accordingly.
LDTs are a category of IVDs that are designed, manufactured and used within a single laboratory. Although LDTs have traditionally been utilized for low-risk diagnostics and rare conditions testing, their landscape has dramatically evolved in recent years. The scale and complexity of LDTs have amplified, reaching a broader patient population and hence, carrying a greater risk if erroneous. Thereby, the necessity for more rigorous oversight.
Once the proposed rule is consummated, these tests will be scrutinized by the FDA as medical devices. The policy aims to increase the safety and efficacy of LDTs, leading to superior patient outcomes. Besides, this could also bring about more transparency in the manufacturing and utilization processes of the LDTs, one of the long-standing demands of the industry.
The FDA’s decision to discontinue its enforcement discretion approach could denote that LDTs that had previously been outside the purview of FDA regulations may now be regulated. Although more demanding for businesses, this framework could improve public health safeguards by ensuring rigorous scientific validation for each test before their wide-scale deployment.
The precise details of the proposed rule and its potential impact on the LDT industry remain to be seen. However, it is clear that the FDA is taking steps towards further enhancing its oversight over LDTs, taking cognizance of their expanding complexity and significance in the healthcare landscape.